Compare WMK & ZLAB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | WMK | ZLAB |
|---|---|---|
| Founded | 1912 | 2013 |
| Country | United States | China |
| Employees | N/A | N/A |
| Industry | Food Chains | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Staples | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.8B | 2.0B |
| IPO Year | 1994 | 2017 |
| Metric | WMK | ZLAB |
|---|---|---|
| Price | $78.22 | $16.62 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 5 |
| Target Price | N/A | ★ $49.60 |
| AVG Volume (30 Days) | 113.9K | ★ 793.9K |
| Earning Date | 05-04-2026 | 05-07-2026 |
| Dividend Yield | ★ 1.96% | N/A |
| EPS Growth | N/A | ★ 38.46 |
| EPS | ★ 1.13 | N/A |
| Revenue | ★ $4,714,573,000.00 | $460,156,000.00 |
| Revenue This Year | N/A | $9.75 |
| Revenue Next Year | N/A | $26.03 |
| P/E Ratio | $66.97 | ★ N/A |
| Revenue Growth | 0.01 | ★ 15.33 |
| 52 Week Low | $59.99 | $15.96 |
| 52 Week High | $79.05 | $44.34 |
| Indicator | WMK | ZLAB |
|---|---|---|
| Relative Strength Index (RSI) | 71.58 | 31.99 |
| Support Level | $67.74 | $15.96 |
| Resistance Level | N/A | $19.64 |
| Average True Range (ATR) | 2.32 | 0.62 |
| MACD | 0.44 | -0.17 |
| Stochastic Oscillator | 90.98 | 8.85 |
Weis Markets Inc is a U.S.-based company that is principally engaged in retailing food products in Pennsylvania and surrounding states. The company's products mainly belong to the following categories: center-store goods, fresh goods, pharmacy services, fuel, and others. The center-store goods include groceries, dairy products, frozen foods, alcoholic beverages, and general merchandise items. The fresh goods include meats, seafood, floral, prepared foods, and bakery products. The center-store goods and fresh goods jointly account for the majority of the company's total revenue.
Zai Lab Ltd is a biopharmaceutical company focusing on discovering or licensing, developing, and commercializing proprietary therapeutics that address areas of unmet medical need including in the fields of oncology, autoimmune and infectious diseases. Zai Lab has a diverse pipeline of potentially first-in-class product candidates developed through in-house R&D and global partnerships. The company has successfully commercialized several products in China, including Zejula, Optune, Qinlock, and Nuzyra, with plans for further expansion The pipeline of proprietary drug candidates of the company includes ZL-1222, ZL-1311, ZL-6201 and many others.